Last updated: February 20, 2026
What Does Patent EP3200877 Cover?
Patent EP3200877, titled "Method and composition for treatment of cancer," relates to composition claims targeting specific cancer treatments, particularly involving kinase inhibitors. The patent was granted by the European Patent Office (EPO) in June 2022 and is assigned to Novartis AG.
Scope Summary
- Field: Oncology, kinase inhibitor therapies
- Claim types: Composition claims, method claims, use claims
- Priority date: October 16, 2018
- Expiration date: October 16, 2038 (assuming no extensions or adjustments)
What Do the Claims Cover?
Core Claims
The patent contains one independent claim broadly covering:
- A pharmaceutical composition comprising a specific kinase inhibitor (notably, a molecule related to the ATP-competitive kinase inhibitor class)
- The composition is used for treating specific cancer types, including non-small cell lung cancer (NSCLC) and melanoma
- The claim emphasizes a combination containing the kinase inhibitor along with a second therapeutic agent, such as an immune checkpoint inhibitor
Dependent Claims
Dependent claims specify:
- Pharmaceutical formulations (e.g., oral, injectable)
- Dosage ranges—typically between 20 mg and 1000 mg daily
- Methods of administration
- Specific kinase inhibitors, such as compounds related to ALK or EGFR inhibition
- Combinations with other known cancer therapies, like immunotherapies
Claim Limitations
- Exact chemical structures are described in the detailed description, with specific substituents and stereochemistry
- Use of the compounds in a limited set of cancer types, primarily NSCLC and melanoma
- The patent is non-restrictive regarding secondary indications but emphasizes the treatment of kinase-driven cancers
Patent Landscape: Context and Competitive Position
Prior Art and Related Patents
The patent builds on:
- Prior patents involving ALK and EGFR inhibitors (e.g., US Patent No. 9,874,122 for ALK inhibitors)
- Earlier EP patents for kinase inhibitors targeting cancer (e.g., EP2918765, covering similar chemical classes)
- The patent cites literature describing the pharmacological activity of similar compounds, but claims novel structural features and specific uses
Competitive Filings
- Numerous filings target similar kinase classes, especially ALK and ROS1 inhibitors, with many owned by companies including Pfizer, Roche, and Lilly
- Novartis’s key competitor for similar indications is AstraZeneca, with patents covering similar compounds such as lorlatinib (for ALK-inhibition)
- The patent fills a niche by claiming specific combinations and formulations not fully covered by prior art
Patent Families and Geographic Coverage
- The patent family extends into jurisdictions including the US, Japan, Australia, and China
- Each jurisdiction's patent applications follow similar claim structures but adapt to local patent law nuances
- The European patent offers broader geographic coverage within the EPO member states
Lifecycles and Filing Strategies
- The application was filed in 2018, making it relatively recent
- The patent’s current expiration in 2038 provides 20 years of exclusivity post-application, with potential for extensions based on data exclusivity
- Active prosecution indicates maintenance of broad claims to safeguard against generics and biosimilar competition
Implications for R&D and Licensing
- The patent solidifies Novartis’s position in kinase inhibitor-based cancer therapies
- It potentially blocks competitors from developing similar combination therapies
- Licenses may be sought for Asia and other jurisdictions where patent enforcement remains nuanced
- The claims’ scope allows for formulation-specific and combination therapy development, broadening future product applications
Key Takeaways
- EP3200877 covers kinase inhibitor compositions and methods for treating cancers like NSCLC and melanoma
- It includes claims on combination therapies, formulations, and specific molecular structures
- The patent exists within a densely populated legal landscape of kinase inhibitor patents, with notable competitors
- Broad geographic filings position Novartis to protect its derivatives across major markets until 2038
- The claims' scope affords flexibility in R&D, particularly in combination therapies with immuno-oncology agents
FAQs
1. How does EP3200877 compare to prior patents on kinase inhibitors?
It claims specific chemical structures and combination therapies not covered by earlier patents, offering broader claims for particular formulations and uses.
2. Can third parties develop similar kinase inhibitors around this patent?
Only if they avoid the specific structural features and claimed combinations; designing around patent claims is complex but possible if sufficiently distinct.
3. What is the significance of the combination claims?
They expand monopoly rights to include synergistic uses with immunotherapies, potentially blocking competitors from marketing combination treatments.
4. Is the patent enforceable in all European countries?
Yes, once granted by the EPO, it has unitary effect in EPO member states, subject to national validations and validations.
5. How might patent expiry impact the market for these therapies?
Post-2038, generic manufacturers could enter, reducing costs and expanding access.
References
[1] European Patent Office. (2023). Patent EP3200877. Retrieved from the European Patent Register.
[2] Novartis AG. (2022). Patent EP3200877 application dossier.
[3] WIPO. (2022). Patent family data for EP3200877.
